More than 70% of drugs on the market today are targeted to GPCRs, with sales of more than $30 billion. These targets will continue to be key in the search for effective therapeutics. This premier conference will address the important issues of GPCRs as targets and therapeutics, and will present problem-solving strategies in the search for more effective GPCR targeted drug discovery.

SCIENTIFIC ADVISORY BOARD
Dr. Annette Gilchrist, Northwestern University
Dr. Kenneth Jacobson, NIDDK, NIH
Dr. Kenneth Lundstrom, BioXtal

SPEAKERS AND CHAIRPERSONS
Dr. Peter Cassidy, Mimetica
Dr. Arthur Christopoulos, University of Melbourne
Dr. Michel Detheux, Euroscreen
Dr. Richard Eglen, DiscoveRx Corp.
Dr. Miguel Garcia-Guzman,Vertex Pharmaceuticals
Dr. Annette Gilchrist, Northwestern University
Dr. Val S. Goodfellow, Neurocrine Biosciences, Inc.
Dr. Yinghe Hu, East China Normal University
Dr. Patrick Jimonet, Aventis Pharmaceuticals
Dr. Barry Kenny, Paradigm Therapeutics Ltd
Dr. Claire Komives, San Jose State University
Dr. Evi Kostenis, 7TM Pharma and University of Copenhagen
Dr. Kenneth Lundstrom, BioXtal
Mr. Srinivasan Madabushi, Baylor College of Medicine
Prof. Christer Owman, Lund University and HeptaHelix Ltd.
Dr. John T. Ransom, Novasite Pharmaceuticals
Dr. Larry A Sklar, University of New Mexico School of Medicine
Dr. Lynmarie K. Thompson, University of Massachusetts
Dr. Jie Zhang, Aventis Pharmaceuticals

• Determining Global and Class-Specific Functions
• Flow Cytometric Analysis of GPCR Assemblies and Their Applications in Drug Discovery
• Characterization of Orphan GPCRs as Targets for Drug Discovery
• Ligand-Selective GPCR Conformations and Signaling
• Identification of Natural and Surrogate Ligands for Orphan GPCRs and Beyond

• Identification of Peptide Ligands for GPCR using a Functional Assay
• High-Throughput Screening Approaches to Identifying Subtype Selective GPCR Agonists
• G Protein Dependent Versus Arrestin Dependent Signaling: Pros and Cons of Current "Universal" Cell Based Assays and Implications for Ligand Pharmacology
• High Speed Single Cell, Multiplexed Lead Discovery Pharmacology
• A Homogeneous Enzyme Fragment Complementation Cyclic AMP Screen for GPCR Agonists

• Towards an Artificial Nose Sensor Based on Olfactory GPCRs
• Small Molecule Antagonist of Thrombin-Mediated PAR1/Gq Signaling
• Mimetics: From Ligand to Drug
• Structural Genomics Approaches to Membrane Proteins
• Design Strategies for GPCR-Focused Libraries

• Solid-state NMR Studies of Transmembrane Signaling
• Receptors for Lipid Mediators: Role in Inflammation and Metabolic Disease
• Development of Drugs Acting at GPCRs for the Treatment of Cachexia and Obesity
• Discovery of Novel GPCR Targets Through a Reverse Genetics Screen

Call for Sponsors and Exhibitors 
Showcase your company's expertise, brand your solutions and develop revenue opportunities with qualified decision-makers by becoming an exhibitor or sponsor at GPCRs and Kinases. Sponsorship opportunities include: technology workshop presentations, poster competitions, refreshment breaks and networking receptions just to name a few. We also have high-visibility items such as conference padfolios and badge lanyards, which will brand your company name and logo.

For more information on exhibiting and sponsoring,
please contact Arnie Wolfson at 781-972-5431, or awolfson@healthtech.com